Overview
Samsara Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule autophagy activators to address age-related neurodegenerative diseases. The company targets fundamental mechanisms of cellular aging through compounds designed to enhance autophagy, a cellular cleanup process critical for removing damaged proteins and organelles. Samsara's pipeline includes programs for amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Charcot-Marie-Tooth disease type 1A, with the goal of providing disease-modifying treatments that address root causes rather than symptoms. Operating from headquarters in Boston and an R&D hub in Oxford, the company aims to establish autophagy-inducing therapeutics as a new class of geroprotective agents.